On October 7th, 2021 Bicycle Therapeutics plc (NASDAQ: BCYC) provided a clinical update of its wholly-owned, next-generation Bicycle Toxin Conjugates ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Momentum Movers Trader Talk

Bicycle Therapeutics Plc (BCYC) Files Mixed Shelf Registration StatementOctober 12, 2021 6:19 AM Bicycle Therapeutics Plc (BCYC) Shares Up 10% Following Positive Phase 1 Data Readouts; Analyst Price Target HikesOctober 8, 2021 9:52 AM Bicycle Therapeutics (BCYC) PT Raised to $76 at Piper SandlerOctober 8, 2021 9:06 AM Bicycle Therapeutics (BCYC) PT Raised to $72 at B.RileyOctober 8, 2021 8:00 AM Bicycle Therapeutics (BCYC) PT Raised to $65 at OppenheimerOctober 8, 2021 7:16 AM UPDATE: Bicycle Therapeutics (BCYC) PT Raised to $65 at Roth Capital on Initial Success of EphA2 Targeting PlatformOctober 7, 2021 5:43 PM Bicycle Therapeutics Plc (BCYC) Resumes TradingOctober 7, 2021 3:21 PM Bicycle Therapeutics Plc (BCYC) Reports Interim BT5528 Phase I Results and Preliminary BT8009 Phase I ResultsOctober 7, 2021 12:51 PM Bicycle Therapeutics Plc (BCYC) Halted, News PendingOctober 7, 2021 12:45 PM